Apart from chemotherapy, SCLC and NSCLC patients were considered to receive analgesic, steroid, bisphosphonate, 3-month nutritional support and G-CSF therapy (Table 4). The gene discussed is CSF3; the disease is non-small cell lung carcinoma.